Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Shang X, Li Z, Sun J, Zhao C, et al. Lung Cancer 2021;154:105-112.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shang X, Li Z, Sun J, Zhao C, et al. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer 2021;154:105-112.
PMID: 33640623